* Sun Pharma has launched its global innovative drug, ILUMYA (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis. * ILUMYA is a novel biologic treatment widely endorsed by dermatologists in the US and worldwide. * According to Kirti Ganorkar, Managing Director of Sun Pharma, ILUMYA offers a safe and effective treatment option for patients. * ILUMYA is currently available in 35 countries and has demonstrated significant and long-lasting skin clearance. * A clinical study in India involving 115 patients showed significant skin clearance, with 93.9% of patients achieving ≥75% reduction in Psoriasis Area Severity Index Score at Week 28. * Dr. B. S. Chandrashekar highlighted the significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance in the Phase-3 trial. * ILUMYA is the first IL-23 inhibitor to complete five years of study, demonstrating its potential as a sustainable choice for long-term treatment.
